Key result
Cryoballoon ablation using the POLARx system resulted in a 1-year atrial fibrillation recurrence rate of 22.2% compared to 31.8% with the AFAP system (HR 0.61; 95% CI 0.28-1.37; p=0.225).
Why the study?
Cryoballoon ablation is a first-line therapy for AF, but the relative efficacy, safety, and influence of pulmonary vein anatomy between two ablation systems required evaluation.
Does the POLARx cryoballoon system improve procedural performance and reduce atrial fibrillation recurrence compared to the Arctic Front Advance Pro system in patients undergoing first-time ablation?
Population
122 patients planned for first-time cryoballoon ablation
Comparison
POLARx system vs Arctic Front Advance Pro system
Design
1:1 assigned study
Follow-up
12 months
Authors
Loading...
No significant difference detected; hypothesis-generating and leaves comparative efficacy open for randomized trials.
RCT (n=122)
1:1
Does the POLARx cryoballoon system improve procedural performance and reduce atrial fibrillation recurrence compared to the Arctic Front Advance Pro system in patients undergoing first-time ablation?
Hazard Ratio: 0.61 (95% CI 0.28–1.37)
Absolute Event Rate: 22.2% vs 31.8%
p-value: p=0.225
The POLARx cryoballoon system demonstrates different cooling kinetics and more consistent performance across difficult pulmonary vein anatomies compared to AFAP, though 1-year clinical outcomes are comparable.
Menger et al. (2023) conducted an RCT in Atrial fibrillation (n=122). POLARx system vs. Arctic Front Advance Pro (AFAP) system was evaluated on Atrial fibrillation recurrence at 1 year (HR 0.61, 95% CI 0.28-1.37, p=0.225). Cryoballoon ablation using the POLARx system resulted in a 1-year atrial fibrillation recurrence rate of 22.2% compared to 31.8% with the AFAP system (HR 0.61; 95% CI 0.28-1.37; p=0.225).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: